Transaction #31272 · Form 4 · 0001802615-26-000002
Altimmune, Inc. · Exercise / conversion · Common Stock, par value $0.0001
Altimmune, Inc. · Transacted October 1, 2026 · Filed October 5, 2026
What does this filing report?
An SEC Form 4 filing for Altimmune, Inc. records an exercise / conversion involving Common Stock, par value $0.0001 on October 1, 2026. The reported quantity was 37,500. The filing date is October 5, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Altimmune, Inc.
- Company CIK
- 0001326190
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 37,500
- Reported price
- 0 · See footnotes
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 37,500
- Ownership description
- Not reported
- SEC acceptance time
- Oct 5, 2026, 4:10 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Arbet-Engels Christophe ↗
Chief Medical Officer
CIK 0001802615
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Filing footnotes & remarks
- F1
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
- F2
- Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
- F3
- The RSUs become vested over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.